PD-1在急性白血病异基因造血干细胞移植后T淋巴细胞的表达
Expression of PD-1 on T-lymphocytes in acute leukemia after allogeneic hematopoietic stem cell transplantation
Received date: 2020-09-23
Online published: 2021-03-29
目的 探究PD-1在急性白血病患者异基因造血干细胞移植(allo-HSCT)后外周血T淋巴细胞表达的动态变化及临床意义。方法 采集23例健康志愿者(对照组),40例急性白血病患者allo-HSCT(移植组)后1、2、3、4.5、6个月的外周血标本,采用流式细胞术对各标本CD3+CD4+、CD3+CD8+ T淋巴细胞程序性死亡蛋白1(PD-1)的表达水平进行监测,分析移植组和对照组的PD-1表达水平差异。结果 急性白血病患者allo-HSCT后1、2个月PD-1在CD3+CD4+、CD3+CD8+T淋巴细胞的表达水平高于对照组;3、4.5、6个月PD-1在CD3+CD4+ T细胞的表达水平高于对照组, 且随移植时间呈现下降趋势,在CD3+CD8+ T淋巴细胞的表达水平与对照组差异无明显统计学意义(P均>0.05)。结论 急性白血病患者allo-HSCT后早期PD-1在CD3+CD4+ T淋巴细胞的表达较正常水平升高且随移植时间呈现下降趋势;在CD3+CD8+ T淋巴细胞的表达于移植后早期呈现一过性升高。
关键词： 白血病; 程序性细胞死亡受体1; 造血干细胞移植; 淋巴细胞
刘建宁 , 孙立 , 牛志云 , 温树鹏 , 王颖 , 张学军 , 王福旭 . PD-1在急性白血病异基因造血干细胞移植后T淋巴细胞的表达[J]. 临床荟萃, 2021 , 36(3) : 251 -255 . DOI: 10.3969/j.issn.1004-583X.2021.03.013
Objective To explore the dynamic change and clinical significance of PD-1 (programmed cell death protein 1) expression on T-lymphocytes in acute leukemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods Twenty-three healthy volunteers (the control group) and 40 patients with acute leukemia (the transplantation group) were selected, peripheral blood samples were collected 1, 2, 3, 4, 5, 6 months after allo-HSCT, and PD-1 expression levels on CD3+CD4+ and CD3+CD8+ T-lymphocytes were tested by the flow cytometry. The differences of PD-1 expression levels between the allo-HSCT group and the control group were analyzed. Results The expression levels of PD-1 on CD3+CD4+ and CD3+CD8+ T-lymphocytes in acute leukemia patients in the transplantation group at 1 and 2 months after allo-HSCT were higher than those of the control group. The PD-1 expression levels on CD3+CD4+ T-lymphocyte in the transplantation group were higher than those of the control group at 3, 4, 5 and 6 month after allo-HSCT, but they showed a downtrend with the transplantation time, while the PD-1 expression levels in CD3+CD8+ T-lymphocyte had no obvious statistical significance (P>0.05 for all). Conclusion The PD-1expression levels on CD3+CD4+ T-lymphocyte in patients with acute leukemia after allo-HSCT were higher than those normal levels at the early stage and showed a downtrend with the transplantation time; while the PD-1 expression levels on CD3+CD8+ T-lymphocyte were increased transiently at the early stage after allo-HSCT.
| [1] | Frassoni F, Barrett AJ, Granena A, et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B. M.T. of 117 cases[J]. Br J Haematol, 1988,70(3):317-320. |
| [2] | Mielcarek M, Storer BE, Flowers ME, et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2007,13(10):1160-1168. |
| [3] | Fathi AT, Chen YB. Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation[J]. Curr Hematol Malig Rep, 2014,9(2):186-192. |
| [4] | 张之南, 沈悌. 《血液病诊断及疗效标准》[M].3版. 北京: 科学出版社, 2007. |
| [5] | 中华医学会血液学分会. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2017年版)[J]. 中华血液学杂志, 2017,38(3):177-182. |
| [6] | 中国抗癌协会血液肿瘤专业委员会. 中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)[J]. 中华血液学杂志, 2016,37(10):837-845. |
| [7] | 宁红梅, 冯凯, 陈虎, 等. 粘附分子与移植物抗宿主病[J]. 国外医学.输血及血液学分册, 2004,27(2):102-106. |
| [8] | Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy[J]. Net Rev Immunol, 2012,12(6):443-458. |
| [9] | Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD[J]. Blood, 2009,114(3):702-708. |
| [10] | 中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(I)—适应症、预处理方案及供者选择(2014年版)[J]. 中华血液学杂志, 2014,35(8):775-780. |
| [11] | Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading[J]. Bone Marrow Transplant, 1995,15(6):825-828. |
| [12] | Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I.Diagnosis and staging working group report[J]. Biol Blood Marrow Transplant, 2005,11(12):945-956. |
| [13] | 中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(III)—急性移植物抗宿主病(2020年版)[J]. 中华血液学杂志, 2020,41(7):529-536. |
| [14] | Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity[J]. Autoimmun Rev, 2013,12(11):1091-1100. |
| [15] | 孙建军, 冯辉. CD8+T细胞耗竭及靶向CD8+T细胞免疫治疗的研究进展[J]. 免疫学杂志, 2016,32(9):816-820. |
| [16] | Simonetta F, Pradier A, Bosshard C, et al. Dynamics of expression of Programmed Cell Death Protein-1 (PD-1) on T cells after allogeneic hematopoietic stem cell transplantation[J]. Front Immunol, 2019,10:1034. |
| [17] | Kong Y, Zhang J, Claxton DF, et al. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation[J]. Blood Cancer J, 2015,5(7):e330. |
| [18] | Noviello M, Manfredi F, Ruggiero E, et al. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT[J]. Nat Commun, 2019,10(1):1065. |
| [19] | Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies[J]. Clin Cancer Res, 2008,14(10):3044-3051. |
| [20] | Ravandi F, Assi R, Daver N, et al. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study[J]. Lancet Haematol, 2019,6(9):e480-e488. |
| [21] | Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD[J]. Blood, 2017,130(2):221-228. |
| [22] | Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation[J]. Blood, 2009,113(7):1581-1588. |
/
| 〈 |
|
〉 |